You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《盈警響號》艾美疫苗(06660.HK)料去年股東應佔淨虧損按年擴大至12.5億至13.8億人幣
阿思達克 03-04 08:20
艾美疫苗(06660.HK)發盈警,預期去年未經審核淨虧損介乎18.1億至19.9億元人民幣(下同),而2022年同期錄得淨虧損2.3億元;料去年股東應佔淨虧損介乎12.5億至13.8億元,2022年淨虧損3.2億元。 集團去年在銷售收入按年基本持平的前提下,虧損增加的主要原因是鑑於新冠疫情在全世界範圍內發生重大變化,集團在去年結合產品研發進度、市場環境變化及銷售預測等綜合因素對收購控股子公司珠海麗凡達生物技術形成的無形資產及商譽計提減值損失,介乎16.5億至18億元;由於公司研發管線進度進展,包括13價結合肺炎疫苗產品、無血清迭代狂犬疫苗產品等5個主要核心產品均處於三期臨床狀態,其他非新冠的mRNA技術產品研發持續推進,使得去年研發費用較上年度持續大幅增加。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account